Reverse Pitches
In partnership with 
Start-up Stadium, Booth 759
Whether through investment, licensing, distribution agreements, or acquisitions, partnering with a strategic or investor is a popular play in in medtech. Not only do they bring deeper pockets, but many times can offer additional resources and contacts for start-ups and early-stage companies.
In this “reverse pitch” opportunity, we’ll hear from leading industry strategics and investors about their plans for growth, focus areas, and criteria for partnerships. Join us as we shift the focus of the spotlight onto industry leaders as they share why they are the ideal partner.
Antonio
Sanchez-Cordero
Archimed
Wednesday, September 25 | 4 p.m.
Antonio Sanchez-Cordero is a global healthcare private equity investor at Archimed, where he specializes in identifying and nurturing strategic investment opportunities in the medical devices and diagnostics sectors. With a robust background in corporate leadership, Antonio has held key roles at leading healthcare multinationals such as Thermo Fisher Scientific, Becton Dickinson and Werfen, focusing on business development, corporate strategy, and M&A.
Chris
West
Smith + Nephew
Wednesday, September 25 | 4:20 p.m.
Chris West manages Corporate Development for Smith+Nephew’s Orthopedics, Sports Medicine, ENT, and Biologics business. Most recently, he led the $330M acquisition of CartiHeal’s Agili-C Implant for cartilage repair. Before his current role, he spent time leading Strategy and Market Intelligence and implementing portfolio life-cycle management ahead of MDR. Chris has a degree in Supply Chain Management from Arizona State University and resides in Austin, Texas, with his wife and two children.
Daniel
Gottlieb
Broadview Ventures
Wednesday, September 25 | 4:40 p.m.
Daniel is a Director of the MedTech practice at Broadview Ventures, a mission-drive investment organization focused on improving human health in the areas of cardiovascular disease and stroke. Prior to joining Broadview, Daniel was Vice President of Corporate Development at Proteon Therapeutics, and held strategy and operational roles at Abbott Vascular and Guidant. Daniel was a key member of Guidant’s corporate venture and business development group, Compass, where he led investments in early-stage cardiovascular device companies.
Daniel holds a BA from the University of Pennsylvania and an MBA from the Tuck School of Business at Dartmouth. He has board roles at CroíValve, Cardiosense, Nyra Medical, and XII Medical, and prior board roles at Puzzle Medical, Nido Surgical (acquired), CardioMEMS (acquired), and Neovasc (acquired).